Content Conference Coverage Conferences ICAAC 2008
ICAAC 2008: Abacavir/lamivudine plus Boosted Atazanavir Provides Potent Antiviral Activity at All Viral Load Levels
- Details
- Category: HIV Treatment
- Created on Friday, 31 October 2008 13:55
Recently presented data have offered conflicting evidence concerning the relative effectiveness of nucleoside reverse transcriptase inhibitor (NRTI) backbone combinations using abacavir or tenofovir. New data presented this week at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) in Washington, DC, provide further support for both sides of the debate. (The HEAT and GlaxoSmithKline trial review results were presented again as posters at ICAAC.)
ICAAC 2008: Boosted Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Are both Highly Effective through 96 Weeks
- Details
- Category: Approved HIV Drugs
- Created on Friday, 31 October 2008 13:55
Long-term clinical trial data show that modern HAART regimens offer continued antiviral efficacy over time, although toxicities remain a concern.
ICAAC 2008: Zinc Finger Nuclease that Disables CCR5 Gene May Offer Potential New HIV Treatment Approach
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 18 November 2008 12:55
It may be possible to create CD4 cells that are resistant to HIV infection by using zinc finger protein nucleases to disable the gene that encodes the CCR5 co-receptor, according to research presented at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last month in Washington, DC.
ICAAC 2008: Efficacy and Safety of Boosted Darunavir (Prezista) Are Comparable to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial
- Details
- Category: Approved HIV Drugs
- Created on Tuesday, 28 October 2008 13:55
Tibotec's second-generation protease inhibitor darunavir (Prezista) was approved in June 2006 for treatment-experienced HIV patients, to be administered at 600 mg boosted with 100 mg ritonavir twice-daily. As previously reported, in the Phase III ARTEMIS trial darunavir/ritonavir demonstrated safety and efficacy comparable to that of lopinavir/ritonavir (Kaletra) at 48 weeks. In a late-breaker session at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008), taking place this week in Washington, DC, researchers presented longer-term 96-week data from the study. Follow-up is scheduled to continue through 192 weeks.Boosted darunavir has also been studied in treatment-naive individuals, and earlier this month received approval for use in this patient population.
ICAAC 2008: Investigational NNRTI RDEA806 Exhibits Promising Activity and Has High Barrier to Resistance
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 11 November 2008 12:55
At the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last week in Washington, DC, researchers presented data on several new antiretroviral agents in the pipeline, including an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) designated RDEA806, being developed by Ardea Biosciences.
More Articles...
- ICAAC 2008: Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks
- ICAAC 2008: Continuous HAART Associated with Elevated Risk of Bone Loss in SMART Treatment Interruption Trial
- ICAAC 2008: Studies Look at Long-term Efficacy Safety of Tenofovir (Viread/Truvada/Atripla), including Kidney Toxicity and Bone Loss
- ICAAC 2008: Blood Lipid Levels and Insulin Resistance Predict Response to Interferon-based Therapy in HIV-HCV Coinfected Patients
- ICAAC 2008: Efficacy of Tenofovir (Viread) plus Emtricitabine (Emtriva) in HIV-HBV Coinfected Patients
- ICAAC 2008: HAART Is Associated with Reduced Liver Inflammation in HIV-HCV Coinfected Patients
- ICAAC 2008: Drug Interaction Observed between NRTI Tenofovir (Viread) and Experimental Hepatitis C Protease Inhibitor Telaprevir
- ICAAC 2008: Another Study Confirms Hepatitis B Virus Suppresses Hepatitis C Virus Replication in HBV-HCV Coinfected Individuals
Web Design and Development by